Unknown

Dataset Information

0

Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.

ABSTRACT: A series of sulphonamide benzoquinazolinones 5-18 was synthesized and evaluated for cytotoxic activity against MDA-MB-231 cell line. The compounds showed IC50 ranging from 0.26 to 161.49?µM. The promising compounds were evaluated for their inhibitory profile against epidermal growth factor (EGFR) and HER2 enzymes. Compound 10 showed more potent activity on both EGFR and HER2 than erlotinib (IC50 3.90 and 5.40?µM versus 6.21 and 9.42?µM). The pro-apoptotic activity of 10 was evaluated against caspase-3, Bax, B-cell lymphoma protein 2 (Bcl-2) expression levels, and cell cycle analysis. Compound 10 increased the level of caspase-3 by 10 folds, Bax level by 9 folds, decreased the level of the Bcl-2 by 0.14 and arrested the cell cycle in the G2/M phase. The radio-sensitizing activity of 10 was measured using a single dose of 8?Gy gamma radiation (IC50 decreased from 0.31 to 0.22?µM). Molecular docking was performed on EGFR and HER2 receptors.

SUBMITTER: Soliman AM 

PROVIDER: S-EPMC6522976 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.

Soliman Aiten M AM   Alqahtani Ali S AS   Ghorab Mostafa M  

Journal of enzyme inhibition and medicinal chemistry 20191201 1

A series of sulphonamide benzoquinazolinones 5-18 was synthesized and evaluated for cytotoxic activity against MDA-MB-231 cell line. The compounds showed IC<sub>50</sub> ranging from 0.26 to 161.49 µM. The promising compounds were evaluated for their inhibitory profile against epidermal growth factor (EGFR) and HER2 enzymes. Compound 10 showed more potent activity on both EGFR and HER2 than erlotinib (IC<sub>50</sub> 3.90 and 5.40 µM versus 6.21 and 9.42 µM). The pro-apoptotic activity of 10 was  ...[more]

Similar Datasets

Unknown Novel sulphonamide-bearing methoxyquinazolinone derivatives as anticancer and apoptosis inducers: synthesis, biological evaluation and in silico studies.
| S-EPMC8667930 | biostudies-literature
Unknown Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
| S-EPMC6010119 | biostudies-literature
Unknown Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
| S-EPMC3731256 | biostudies-literature
Unknown Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
| S-EPMC5596996 | biostudies-literature
Unknown Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
| S-EPMC4027597 | biostudies-literature
Unknown Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line.
| S-EPMC7823583 | biostudies-literature
Unknown Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors.
| S-EPMC6993756 | biostudies-literature
Unknown Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
| S-EPMC2691960 | biostudies-literature
Unknown Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors.
| S-EPMC6651501 | biostudies-literature
Unknown Synthesis of some quinazolinones inspired from the natural alkaloid L<i>-</i>norephedrine as EGFR inhibitors and radiosensitizers.
| S-EPMC7781899 | biostudies-literature